Pricey Pradaxa aces cost-effectiveness study

When is an $8-a-day drug a bargain compared with one that costs just a dollar? When the expensive drug is Boehringer Ingelheim's new blood thinner Pradaxa, according to a study by Stanford researchers. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.